GSK Opens $57-Million Vaccines Facility in UK
GlaxoSmithKline (GSK) opened a new vaccine manufacturing facility in Montrose, Scotland. The £44 million (US$57 million) facility will be used to manufacture aluminum salts, which are used for vaccine production.
On August 15, 2017, GlaxoSmithKline (GSK) opened a new vaccine manufacturing facility in Montrose, Scotland. The £44-million (US$57-million) facility, which includes a microbiology laboratory, will manufacture sterile aluminum salts. These salts are compounds that boost the human body’s response in vaccine production, and will be provided to the company’s vaccine sites in Singapore, France, and Belgium.
The opening of the facility follows the company’s recent announcement of a £29-million (US$37-million) investment in Irvine, CA, to support the manufacturing of drugs for respiratory diseases and HIV, bringing the overall investment in new manufacturing in Montrose and antibiotics operation at Irvine to nearly £342 million (US$440 million) since 2012.
With a presence at Montrose since 1952, the company produces key ingredients for 70% of its vaccines portfolio for diseases, including tetanus, pneumonia and whooping cough. The new facility is the first for sterile manufacturing at this location and will be fully operational by 2019.
Source: Government of Scotland
